aod9604 fda approval status AOD-9604 vs MOTS-c vs Tesamorelin vs Semaglutide vs Tirzepatide From BPC-157 to TB-500 to

NAD support with 5-Amino-1MQ shows mildly positive results in the literature

Severe effects warrant immediate discontinuation

It inhibits NNMT (nicotinamide N-methyltransferase), an enzyme regulating metabolism, fat storage, and NAD+ consumption.[4][27][6] NNMT methylates nicotinamide, a NAD+ breakdown product, diverting it from recycling and reducing available NAD+

Animal fat loss studies: Rodent studies consistently demonstrated significant fat mass reduction with AOD-9604 versus controls, providing mechanistic validation and a basis for continued interest despite the clinical trial results

This remarkable selectivity stems from 5-amino-1MQs specific interaction with the nicotinamide-binding pocket of NNMT, rather than the SAM-binding site common to many methyltransferases